What HPV types does Gardasil 9 protect against?

Gardasil 9 protects against 9 HPV types: 6, 11, 16, 18, 31, 33, 45, 52, and 58. Types 16 and 18 are responsible for about 70% of cervical cancers.

What is the recommended dosing schedule for Gardasil 9?

For individuals aged 9 to 14, two doses are recommended, given 6 to 12 months apart. For those starting at age 15 through 45, or individuals with certain immunocompromising conditions, three doses are recommended, administered over a 6-month period.

Why is it important for males to get the HPV vaccine?

Male vaccination is crucial for both personal protection against HPV-related cancers (such as oropharyngeal, anal, and penile cancer) and for establishing herd immunity, which protects unvaccinated females from cervical cancer.

The HPV Vaccine: A Public Health Milestone

Scientific overview of Gardasil 9, clinical efficacy data, and the importance of widespread immunization.

For more foundational information on Human Papillomavirus, please start with our Pillar Guide on HPV Prevention.

The development of prophylactic vaccines against the Human Papillomavirus represents a profound leap forward in the primary prevention of cancer. By protecting against the high-risk viral strains most responsible for cellular dysplasia, widespread vaccination programs aim to eradicate cervical cancer as a public health problem and significantly reduce the incidence of other HPV-associated malignancies.

1. The 9-Valent Vaccine: Gardasil 9

Currently, the standard of care in many nations is the 9-valent HPV vaccine, commercially known as Gardasil 9. This formulation provides direct protection against nine specific genotypes of the virus, categorized by their oncogenic risk.

Types Covered by Gardasil 9

High-Risk Types (Oncogenic): 16, 18, 31, 33, 45, 52, and 58.
Significance: HPV types 16 and 18 are uniquely aggressive, causing approximately 70% of all cervical cancers worldwide. The addition of types 31, 33, 45, 52, and 58 protects against an additional 15-20% of cervical cancers. In total, Gardasil 9 targets the types responsible for 90% of cervical cancers.
Low-Risk Types (Non-Oncogenic): 6 and 11.
Significance: While not associated with cancer, types 6 and 11 are responsible for nearly 90% of anogenital warts and most cases of recurrent respiratory papillomatosis (RRP).

2. Clinical Efficacy and Immunogenicity

The efficacy of Gardasil 9 in preventing precancerous lesions (CIN 2, CIN 3, and adenocarcinoma in situ) caused by the targeted types is exceptionally high. When administered to individuals who are naive to the targeted HPV types (i.e., prior to initial sexual exposure), the vaccine demonstrates an efficacy approaching 100%.

Furthermore, population-level data from countries with robust, early vaccination programs (such as Australia) show precipitous declines in the incidence of high-grade cervical abnormalities and anogenital warts, underscoring the vaccine's dramatic impact in real-world settings.

3. Dosing Schedule by Age

The immunogenicity of the vaccine—the robustness of the antibody response it provokes—is age-dependent. Younger adolescents mount a significantly stronger immune response compared to older teens and adults.

Ages 9-14: A 2-dose schedule is recommended. The second dose is administered 6 to 12 months after the first. This schedule relies on the robust immune response generated in pre-adolescence, achieving non-inferior antibody titers compared to the 3-dose schedule in older individuals.
Ages 15-45: A 3-dose schedule is required. The second dose is given 1 to 2 months after the first, and the third dose is administered 6 months after the first dose.
Immunocompromised Individuals: A 3-dose schedule is universally recommended regardless of age.

4. Safety Profile

Over a decade of post-licensure monitoring by global health authorities, including the WHO and the CDC, consistently affirms the excellent safety profile of HPV vaccines. Millions of doses have been administered globally with no evidence of serious safety concerns linked to the vaccine.

Common adverse events are typically mild and transient, including injection-site pain, redness, swelling, and systemic symptoms like low-grade fever or headache. Syncope (fainting) is occasionally observed following vaccination, leading to the recommendation that patients remain seated for 15 minutes post-administration.

5. Catch-up Vaccination and Shared Clinical Decision Making

While maximum benefit is derived from vaccination prior to viral exposure, "catch-up" vaccination remains highly beneficial. Even if an individual has been exposed to one or more HPV types, they are unlikely to have been exposed to all nine types targeted by Gardasil 9. Therefore, the vaccine can still provide protection against the remaining unexposed high-risk strains.

For adults aged 27 through 45, public health guidelines generally suggest "shared clinical decision-making." Because the public health benefit decreases as age and prior cumulative viral exposure increase, the decision to vaccinate should be individualized, considering the patient's specific risk for new HPV infections (e.g., new sexual partners) and potential benefits.

6. The Importance of Male Vaccination

Initially targeted solely at females to prevent cervical cancer, universal HPV vaccination programs now strongly recommend male vaccination. The rationale is twofold:

Direct Protection: Males are at risk for several HPV-driven malignancies, most notably oropharyngeal squamous cell carcinoma (which has surpassed cervical cancer as the most common HPV-related cancer in the United States), as well as anal and penile cancers.
Herd Immunity: Vaccinating males significantly reduces the overall viral reservoir in the population, conferring indirect protection to unvaccinated females and reducing transmission across all demographics.

7. Global Access Disparities

Despite the overwhelming clinical success of Gardasil 9, profound global access disparities persist. The highest burden of cervical cancer mortality is borne by low- and middle-income countries (LMICs), yet these regions often face significant barriers to implementing national HPV vaccination programs, including high vaccine costs, cold-chain logistics, and healthcare infrastructure limitations. Addressing these inequities is the critical next step in the global effort to eliminate cervical cancer.